Clinical Trial

Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated September 28, 2023 (before its estimated August 15, 2024 completion). Its status may not reflect the trial's current state.
Summary
GVHD prevention using a combination of post-transplantation cyclophosphamide in combination with abatacept, vedolizumab and calcineurin inhibitor in children and young adults with hematoloblastosis after myeloablative conditioning regimen with treosulfan/TBI, cyclophosphamide/etoposide, fludarabine after HSCT from matched unrelated and haploidentical donors
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-08-23; most recent amendment 2023-09-26.
Status change: Recruiting → Active, Not Recruiting 2023-09-26
Status change: Not Yet Recruiting → Recruiting 2023-03-27
Trial Details
NCT Number NCT05515029
Lead Sponsor Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Conditions Acute Lymphoblastic Leukemia, Myeloblastic Leukemia, Biphenotypic Acute Leukemia, Malignant Lymphoma, Myelodysplastic Syndromes, Juvenile Myelomonocytic Leukemia
Enrollment 56 participants
Start Date 2022-08-23
Primary Completion 2024-08-15 (estimated)
Study Completion 2026-10-16 (estimated)
Updated on ClinicalTrials.gov 2023-09-28